ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABVX icon
1
Abivax
ABVX
$7.68B
$240M 11.01%
1,804,703
+410,684
+29% +$46.5M
2024 Q1
9 quarters
PTGX icon
2
Protagonist Therapeutics
PTGX
$8.82B
$118M 5.39%
960,863
-33,256
-3% -$3.47M
2023 Q4
10 quarters
ROIV icon
3
Roivant Sciences
ROIV
$24.3B
$112M 5.11%
3,157,008
-128,898
-4% -$3.81M
2023 Q4
10 quarters
SPY icon
4
State Street SPDR S&P 500 ETF Trust
SPY
$813B
$96.4M 4.41%
129,087
+53,147
+70% +$38.5M
2025 Q2
4 quarters
IMVT icon
5
Immunovant
IMVT
$5.76B
$89.8M 4.11%
2,330,716
-348,294
-13% -$10.6M
2023 Q4
10 quarters
ZLAB icon
6
Zai Lab
ZLAB
$2.53B
$64M 2.93%
3,369,034
+1,943,667
+136% +$38.4M
2023 Q4
10 quarters
AGIO icon
7
Agios Pharmaceuticals
AGIO
$1.85B
$47.8M 2.19%
1,288,053
+1,147,381
+816% +$34.8M
2025 Q1
5 quarters
CRNX icon
8
DELISTED
Crinetics Pharmaceuticals
CRNX
$45.7M 2.09%
1,222,080
+82,749
+7% +$3.08M
2024 Q2
8 quarters
BOXX icon
9
Alpha Architect 1-3 Month Box ETF
BOXX
$14.4B
$39.5M 1.81%
337,125
– –
2024 Q1
9 quarters
CYTK icon
10
Cytokinetics
CYTK
$8.82B
$39M 1.79%
457,907
-174,649
-28% -$12.5M
2023 Q4
10 quarters
SEPN icon
11
Septerna Inc
SEPN
$1.7B
$31.5M 1.44%
940,747
-149,071
-14% -$4.23M
2025 Q1
5 quarters
AVR icon
12
Anteris Technologies
AVR
$610M
$31M 1.42%
3,145,096
-644,036
-17% -$4.9M
2024 Q4
6 quarters
EDIT icon
13
Editas Medicine
EDIT
$349M
$28.8M 1.32%
+8,889,000
New +$26M
2026 Q2
0 quarters
DNLI icon
14
Denali Therapeutics
DNLI
$2.86B
$26.5M 1.21%
1,029,080
-842,375
-45% -$17.3M
2024 Q1
9 quarters
SYRE icon
15
Spyre Therapeutics
SYRE
$7.35B
$25.2M 1.15%
283,982
-54,341
-16% -$3.97M
2025 Q1
5 quarters
VIR icon
16
Vir Biotechnology
VIR
$1.76B
$25M 1.15%
2,456,677
-288,037
-10% -$2.74M
2026 Q1
1 quarter
PRAX icon
17
Praxis Precision Medicines
PRAX
$6.67B
$24.9M 1.14%
74,253
+72,753
+4,850% +$23M
2025 Q4
2 quarters
INSM icon
18
Insmed
INSM
$21.4B
$24.4M 1.12%
228,520
+193,128
+546% +$23.4M
2026 Q1
1 quarter
CLDX icon
19
Celldex Therapeutics
CLDX
$2.19B
$23.1M 1.06%
619,542
+191,726
+45% +$6.19M
2025 Q1
5 quarters
VKTX icon
20
Viking Therapeutics
VKTX
$3.24B
$22.4M 1.02%
574,038
+346,321
+152% +$11.2M
2023 Q4
10 quarters
TSHA icon
21
Taysha Gene Therapies
TSHA
$1.14B
$20.7M 0.95%
3,040,466
+61,037
+2% +$361K
2023 Q4
10 quarters
MNPR icon
22
Monopar Therapeutics
MNPR
$491M
$20.1M 0.92%
217,595
-46,683
-18% -$2.89M
2024 Q4
6 quarters
OVID icon
23
Ovid Therapeutics
OVID
$428M
$20M 0.91%
7,417,479
+2,873,366
+63% +$7.41M
2023 Q4
10 quarters
ELVN icon
24
Enliven Therapeutics
ELVN
$2.88B
$19.7M 0.9%
387,718
+58,178
+18% +$2.47M
2025 Q4
2 quarters
ENTA icon
25
Enanta Pharmaceuticals
ENTA
$326M
$19.6M 0.9%
1,344,510
+1,293,153
+2,518% +$17.4M
2025 Q4
2 quarters
1
2 3 4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.